New hope for rare epilepsy: drug shows promise in phase 3 trial
Disease control
Ongoing
This Phase 3 study tests whether fenfluramine (ZX008) can safely reduce seizures in 87 children and adults with CDKL5 deficiency disorder, a rare genetic condition causing severe epilepsy. Participants receive either the drug or a placebo, followed by an open-label extension wher…
Phase: PHASE3 • Sponsor: Zogenix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC